Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone

Clinical Neuropharmacology

Volumn 26, Issue 3, 2003, Pages 137-141

  Stryjer, Rafael ^a   Strous, Rael D ^a,b   Bar, Faina ^a,b   Poyurovsky, Michael ^c   Weizman, Abraham ^b   Kotler, Moshe ^a,b  

^a BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NONE

Author keywords

Akathisia; Antipsychotic medication; Trazodone

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 2A ANTAGONIST; TRAZODONE;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOTENSION; INSOMNIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIAPISM; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; TREATMENT OUTCOME;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PSYCHOTIC DISORDERS; SEROTONIN UPTAKE INHIBITORS; TRAZODONE; TREATMENT OUTCOME;

EID: 0037714000     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200305000-00006     Document Type: Article

References (27)

1. Poyurovsky M, Shardorodsky M, Weizman A. Treatment of neuroleptic-induced akathisia with 5-HT2 antagonist mianserin. Doubleblind, placebo-controlled study. Br J Psychiatry 1999;174:238-42.
2. Fleischhacker WW, Roth SD, Kane JM. The pharmacological treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12-21.
3. Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 2001;179:4-8.
4. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1999;153:466-76.
5. Miller GH, Fleischhacker WW, Ehrman H, et al. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373-6.
6. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(suppl 2):S106-15.
7. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implication for treatment. J Psychopharmacol 1998;12:192-214.
8. Poyurovsky M, Weizman A. Mirtazapine for neuroleptic-induced akathisia. Am J Psychiatry 2001;158:819.
9. Miller GH, Fleischhacker WW, Ehrman H, et al. Treatment of neuroleptic induced akathisia with the 5HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373-6.
10. Miller CH, Hummer M, Pycha R, et al. The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:247-51.
11. Fuchs C, Weizman A. Low-dose mianserin in the treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol 1998;18:253-4.
12. Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995;167:483-6.
13. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine vs propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001;21:612-5.
14. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharmacol 1982;1:406-17.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
16. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
17. Halstead SM, Barnes TRE, Speller JC. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 1994;164:177-83.
18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psych Scand 1970;212(suppl):11-9.
19. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication no. (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976:218-22.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. Medina CA. Clitoral priapism: a rare condition presenting as a cause of vulvar pain. Obstet Gynecol 2001;97:S26-7.
23. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990;51:430-3.
24. Werner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia and nightmares. Pharmacopsychiatry 2001;34:128-31.
25. Nicolson R, McCurley R. Risperidone-associated priapism. J Clin Psychopharmacol 1997;17:133-4.
26. Emes CE, Milson RC. Risperidone-induced priapism. Can J Psychiatry 1994;39:315-6.
27. Deirmenjian JM, Erharst SM, Wirshing DA, et al. Olanzapineinduced reversible priapism: a case report. J Clin Psychopharmacol 1998;18:351-3.